Patient demographics and baseline characteristics
| Ciprofloxacin DPI 14 days on/off | Placebo 14 days on/off | Ciprofloxacin DPI 28 days on/off | Placebo 28 days on/off | Pooled placebo | Total | |
| Patients n | 176 | 88 | 171 | 86 | 174 | 521 |
| Female | 96 (54.5) | 62 (70.5) | 92 (53.8) | 52 (60.5) | 114 (65.5) | 302 (58.0) |
| Age years | 60.4±13.7 | 60.4±15.0 | 59.3±14.2 | 60.6±13.7 | 60.5±14.3 | 60.1±14.0 |
| Idiopathic aetiology | 62 (35.2) | 32 (36.4) | 43 (25.1) | 36 (41.9) | 68 (39.1) | 173 (33.2) |
| Region# | ||||||
| Europe 1 | 64 (36.4) | 32 (36.4) | 65 (38.0) | 32 (37.2) | 64 (36.8) | 193 (37.0) |
| Europe 2 | 54 (30.7) | 27 (30.7) | 54 (31.6) | 28 (32.6) | 55 (31.6) | 163 (31.3) |
| Africa | 0 | 0 | 2 (1.2) | 0 | 2 (1.1) | 2 (0.4) |
| Latin America | 6 (3.4) | 3 (3.4) | 7 (4.1) | 2 (2.3) | 5 (2.9) | 18 (3.5) |
| Asia | 39 (22.2) | 19 (21.6) | 33 (19.3) | 17 (19.8) | 36 (20.7) | 108 (20.7) |
| Australia | 8 (4.5) | 4 (4.5) | 5 (2.9) | 4 (4.7) | 8 (4.6) | 21 (4.0) |
| USA | 5 (2.8) | 3 (3.4) | 5 (2.9) | 3 (3.5) | 6 (3.4) | 16 (3.1) |
| Ethnicity | ||||||
| White | 133 (75.6) | 68 (77.3) | 135 (78.9) | 67 (77.9) | 135 (77.6) | 403 (77.4) |
| Black/African | 2 (1.1) | 1 (1.1) | 2 (1.2) | 0 | 1 (0.6) | 5 (1.0) |
| Asian | 41 (23.3) | 18 (20.5) | 33 (19.3) | 19 (22.1) | 37 (21.3) | 111 (21.3) |
| Multiple | 0 | 1 (1.1) | 1 (0.6) | 0 | 1 (0.6) | 2 (0.4) |
| FEV1 % pred | 54.3±17.3 | 55.8±18.6 | 56.4±18.8 | 56.2±18.2 | NC | 55.5±18.2 |
| FEV1 % pred <50% | 78 (44.3) | 39 (44.3) | 65 (38.0) | 36 (41.9) | 75 (43.1) | 218 (41.8) |
| SGRQ symptoms component score¶ | 61.26±19.54 | 63.47±19.48 | 60.75±20.61 | 58.56±19.17 | NC | 61.0±19.82 |
| QoL-B RSS¶ | 52.17±18.49 | 48.67±17.72 | 50.14±19.07 | 53.95±16.00 | NC | 51.2±18.6 |
| Exacerbations in prior 12 months | 2.4±0.8 | 2.4±0.7 | 2.3±0.7 | 2.3±1.0 | 2.4±0.9 | 2.4±0.8 |
| Three or more exacerbations in prior 12 months | 42 (23.9) | 22 (25.0) | 35 (20.5) | 16 (18.6) | 38 (21.8) | 115 (22.1) |
| Hospitalised for exacerbation in prior year | 80 (45.5) | 39 (44.3) | 65 (38.0) | 35 (40.7) | 74 (42.5) | 219 (42.0) |
| Long-term oral macrolides | 11 (6.3) | 7 (8.0) | 14 (8.2) | 8 (9.3) | 15 (8.6) | 40 (7.7) |
| History of COPD | 50 (28.4) | 31 (35.2) | 39 (22.8) | 28 (32.6) | 59 (33.9) | 148 (28.4) |
| Baseline Pseudomonas aeruginosa+ | 107 (60.8) | 55 (62.5) | 99 (58.2) | 54 (63.5) | 109 (63.0) | 315 (60.7) |
Data are presented as n (%) or mean±sd. DPI: dry powder for inhalation; FEV1: forced expiratory volume in 1 s; SGRQ: St George's Respiratory Questionnaire; QOL-B RSS: Quality of Life-Bronchiectasis respiratory symptoms domain score; COPD: chronic obstructive pulmonary disease; NC: not calculated. #: Europe 1: Austria, Czech Republic, Germany, Latvia, Lithuania, the Netherlands, Poland, Russia; Europe 2: Bulgaria, Portugal, Romania, Serbia, Turkey; Asia: China, Hong Kong, Philippines, South Korea, Taiwan, Thailand; Latin America: Argentina and Brazil; Africa: South Africa. ¶: not available for Latvia, Philippines, Portugal, Romania, Serbia, Thailand or Turkey (177 subjects (34%) of the RESPIRE 2 population) due to the lack of a translated version; +: patients could have more than one species isolated.